Robinson Osteosarcoma Fund
The Robinson Family Osteosarcoma Research Fund is backing a human clinical trial (Ex-Vivo Expanded Allogeneic NK Cells For The Treatment Of Pediatric Solid Tumors) that opened at MD Anderson on August 31, 2018. It will use NK (natural killer) cells to target solid tumors in patients AND be open to patients younger than 18. That is important to note, because children are often not eligible for life-saving clinical trials simply because of their age.
There have been no significant changes in the way osteosarcoma is treated since the early 1980s. NK cells could be the first significant improvement in a very long time.
Please partner with us. Any donation is a step forward, no matter the dollar amount.
This video show NK cells introduced to an environment with pediatric solid tumor cells (green). The NK cells examine the solid tumor cells, determine them to be "bad" cells and then destroy them by "popping" the tumor cells.
attribution: Somanchi S & Lee D, PLoS ONE 2015